You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
AstraZeneca
Express Scripts
Boehringer Ingelheim
Baxter

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

Denosumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for denosumab
Tradenames:2
Patents:105
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for denosumab
Recent Clinical Trials for denosumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Albert Einstein Healthcare NetworkPhase 2
Vrije Universiteit BrusselPhase 4
Maastricht UniversityPhase 4

See all denosumab clinical trials

Pharmacology for denosumab
Mechanism of ActionRANK Ligand Blocking Activity

Company Disclosures: US Patents for denosumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial Immunex Corporation (Seattle, WA) 2016-12-23 RX Orphan company
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial Amgen Inc. (Thousand Oaks, CA) 2017-04-16 RX Orphan company
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA) 2021-06-26 RX Orphan company
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial Immunex Corporation (Thousand Oaks, CA) 2016-12-23 RX Orphan company
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial Immunex Corporation (Thousand Oaks, CA) 2016-12-23 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for denosumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for denosumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2010000047 Germany   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
2010013,C0975754 Lithuania   Start Trial PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: EU/1/10/618/001, 2010 05 26, EU/1/10/618/002, 2010 05 26, EU/1/10/618/003, 2010 05 26, EU/1/10/618/004 20100526
10C/039 Belgium   Start Trial PRODUCT NAME: DENOSUMAB; AUTHORISATION NUMBER AND DATE: EU/1/10/618/001 20100528
90038-9 Sweden   Start Trial PRODUCT NAME: DENOSUMAB
C0048 France   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
Medtronic
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.